<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">108452</article-id><article-id pub-id-type="doi">10.26442/20751753.2022.2.201391</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Optomyelitis associated with the presence of antibodies to myelin oligodendrocyte glycoprotein. Case report</article-title><trans-title-group xml:lang="ru"><trans-title>Оптикомиелит, ассоциированный с наличием антител к гликопротеину миелиновых олигодендроцитов. Клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2229-384X</contrib-id><name-alternatives><name xml:lang="en"><surname>Kalashnikova</surname><given-names>Anastasiia K.</given-names></name><name xml:lang="ru"><surname>Калашникова</surname><given-names>Анастасия Константиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Graduate Student, Sechenov First Moscow State Medical University (Sechenov University)</p></bio><bio xml:lang="ru"><p>аспирант каф. нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)</p></bio><email>kalashnic94@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4597-4987</contrib-id><name-alternatives><name xml:lang="en"><surname>Sheremet</surname><given-names>Nataliia L.</given-names></name><name xml:lang="ru"><surname>Шеремет</surname><given-names>Наталия Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Research Institute of Eye Diseases</p></bio><bio xml:lang="ru"><p>д-р мед. наук, гл. науч. сотр. отд-ния патологии сетчатки и зрительного нерва ФГБНУ НИИГБ</p></bio><email>kalashnic94@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7329-5725</contrib-id><name-alternatives><name xml:lang="en"><surname>Andreeva</surname><given-names>Natalia A.</given-names></name><name xml:lang="ru"><surname>Андреева</surname><given-names>Наталия Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Research Institute of Eye Diseases</p></bio><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. отд-ния патологии сетчатки и зрительного нерва ФГБНУ НИИГБ</p></bio><email>kalashnic94@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1771-300X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhorzholadze</surname><given-names>Nino V.</given-names></name><name xml:lang="ru"><surname>Жоржоладзе</surname><given-names>Нино Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Research Institute of Eye Diseases</p></bio><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. отд-ния патологии сетчатки и зрительного нерва ФГБНУ НИИГБ</p></bio><email>kalashnic94@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0298-2250</contrib-id><name-alternatives><name xml:lang="en"><surname>Ronzina</surname><given-names>Irina A.</given-names></name><name xml:lang="ru"><surname>Ронзина</surname><given-names>Ирина Адольфовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Research Institute of Eye Diseases</p></bio><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. отд-ния патологии сетчатки и зрительного нерва ФГБНУ НИИГБ</p></bio><email>kalashnic94@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4385-2866</contrib-id><name-alternatives><name xml:lang="en"><surname>Kaloshina</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Калошина</surname><given-names>Анна Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Graduate Student, Research Institute of Eye Diseases</p></bio><bio xml:lang="ru"><p>аспирант отд-ния патологии сетчатки и зрительного нерва ФГБНУ НИИГБ</p></bio><email>kalashnic94@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Institute of Eye Diseases</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт глазных болезней»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2022</year></pub-date><volume>24</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>132</fpage><lpage>136</lpage><history><date date-type="received" iso-8601-date="2022-06-01"><day>01</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-06-01"><day>01</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/108452">https://consilium.orscience.ru/2075-1753/article/view/108452</self-uri><abstract xml:lang="en"><p>Antibodies to myelin-oligodendrocyte glycoprotein (anti-MOG-IgG) is a specific biomarker that has been detected in peripheral blood from children with acute multiple encephalomyelitis (ADEM) as well as in adults with aquaporin-4 (AQP4), associated with seronegative opticoneuromyelitis spectrum disease (NMOSD), brainstem encephalitis, longitudinally disseminated transverse myelitis, and optic neuritis. Most experts now consider MOG-IgG-associated disorder (MOG-AD) an independent disease immunopathogenetically distinct from classical multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive optomyelitis. Isolated, bilateral, and less frequently unilateral OH, with simultaneous or sequential involvement of the eyes, is the most frequent clinical manifestation of MOG-AD. Because of the significant overlap in the clinical and radiological picture, MOG-AD is often misdiagnosed as MS. Timely diagnosis is critical to ensure appropriate treatment. This article describes a clinical case of anti-MOG-IgG encephalomyelitis with late-onset ON initially diagnosed as MS.</p></abstract><trans-abstract xml:lang="ru"><p>Антитела к миелин-олигодендроцитарному гликопротеину (анти-MOG-IgG) – это специфический биомаркер, который обнаружен в периферической крови у детей с острым рассеянным энцефаломиелитом, а также у взрослых с аквапорином-4 (AQP4), ассоциированным с серонегативным заболеванием спектра оптиконейромиелита, энцефалитом ствола мозга, продольно распространенным поперечным миелитом и невритом зрительного нерва. Большинство экспертов в настоящее время считают MOG-IgG – ассоциированное расстройство (МОГ-АР) самостоятельным заболеванием, иммунопатогенетически отличным от классического рассеянного склероза (РС) и AQP4-IgG-положительного оптикомиелита. Изолированный, двусторонний, реже односторонний оптический неврит с одновременным или последовательным вовлечением глаз является наиболее частым клиническим проявлением МОГ-АР. Из-за существенного совпадения клинико-радиологической картины МОГ-АР часто ошибочно диагностируется как РС. Своевременно установленный диагноз имеет решающее значение для обеспечения надлежащего лечения. В статье описан клинический случай анти-MOG-IgG-энцефаломиелита с поздним присоединением оптического неврита, изначально диагностированный как РС.</p></trans-abstract><kwd-group xml:lang="en"><kwd>myelin oligodendrocyte glycoprotein antibody-associated disease</kwd><kwd>anti-myelin oligodendrocyte glycoprotein antibodies</kwd><kwd>neuromyelitis optica spectrum disorders</kwd><kwd>multiple sclerosis</kwd><kwd>optic neuritis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>расстройство</kwd><kwd>ассоциированное с антителами к миелин-олигодендроцитарному гликопротеину</kwd><kwd>антитела к миелин-олигодендроцитарному гликопротеину</kwd><kwd>заболевания спектра оптиконейромиелита</kwd><kwd>рассеянный склероз</kwd><kwd>оптический неврит</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Voss E, Raab P, Trebst C, Stangel M. Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. Ther Adv Neurol Disord. 2011;4(2):123-34. DOI:10.1177/1756285611398702</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Petzold A, Plant GT. Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev. 2014;13(4-5):539-45. DOI:10.1016/j.autrev.2014.01.009</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Weerasinghe D, Lueck C. Mimics and chameleons of optic neuritis. Pract Neurol. 2016;16(2):96-110. DOI:10.1136/practneurol-2015-001254</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Chen JJ, Pittock SJ, Flanagan EP, et al. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2020;65(1):12-7. DOI:10.1016/j.survophthal.2019.08.001</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Di Pauli F, Berger T. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? Front Immunol. 2018;9:2753. DOI:10.3389/fimmu.2018.02753</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Nakajima H, Motomura M, Tanaka K, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5(4):e007766. DOI:10.1136/bmjopen-2015-007766</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Sepúlveda M, Armangue T, Martinez-Hernandez E, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016;263(7):1349-60. DOI:10.1007/s00415-016-8147-7</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Akaishi T, Sato DK, Takahashi T, Nakashima I. Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. Neurochem Int. 2019;130:104319. DOI:10.1016/j.neuint.2018.10.016</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. DOI:10.1186/s12974-018-1144-2</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Елисеева Д.Д., Васильев А.В., Шабалина А.А., и др. Энцефаломиелиты, ассоциированные с антителами к миелинолигодендроцитарному гликопротеину. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(7-2):13-23 [Eliseeva DD, Vasiliev AV, Shabalina AA, et al. Myelin oligodendrocyte glycoprotein immunoglobulin G-associated encephalomyelitis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(7-2):13-23 (in Russian)]. DOI:10.17116/jnevro202012007213</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128-38. DOI:10.1093/brain/awx276</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Щепарева М.Е., Кочергин И.А., Толпеева О.А., и др. Диагностическое значение антител к миелин-олигодендроцитарному гликопротеину при демиелинизирующих заболеваниях центральной нервной системы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(2-2):18-23 [Shchepareva ME, Kochergin IA, Tolpeeva OA, et al. Diagnostic value of antibodies to myelin oligodendrocyte glycoprotein in demyelinating diseases of the central nervous system. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(2-2):18-23 (in Russian)].</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zheng Y, Cai MT, Li EC, et al. Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity? Front Immunol. 2021;12:671425. DOI:10.3389/fimmu.2021.671425</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346-51. DOI:10.1136/jnnp-2017-316286</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Juryńczyk M, Tackley G, Kong Y, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88(2):132-6. DOI:10.1136/jnnp-2016-314005</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Dubey D, Pittock SJ, Krecke KN, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019;76(3):301. DOI:10.1001/jamaneurol.2018.4053</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ciron J, Cobo-Calvo A, Audoin B, et al. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Mult Scler. 2020;26(8):936-44. DOI:10.1177/1352458519849511</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127-37. DOI:10.1136/jnnp-2017-316880</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Fang W, Zheng Y, Yang F, et al. Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2020;13:175628641989859. DOI:10.1177/1756286419898594</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Jarius S, Ruprecht K, Kleiter I, et al. Mog-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 1: Frequency, Syndrome Specificity, Influence of Disease Activity, Long-Term Course, Association With AQP4-IgG, and Origin. J Neuroinflammation. 2016;13(1):279. DOI:10.1186/s12974-016-0717-1</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Brayo P, Shah S. MOG-IgG Associated Disease (MOG-AD) in Adults. Curr Treat Options Neurol. 2021;23(6):17. DOI:10.1007/s11940-021-00672-6</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Narayan RN, McCreary M, Conger D, et al. Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients. Mult Scler Relat Disord. 2019;28:86-90. DOI:10.1016/j.msard.2018.11.026</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Outteryck O, Majed B, Defoort-Dhellemmes S, et al. A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler. 2015;21(14):1781-93. DOI:10.1177/1352458515578888</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Havla J, Pakeerathan T, Schwake C, et al. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation. 2021;18(1):121. DOI:10.1186/s12974-021-02160-9</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Filippatou AG, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG-IgG Related Optic Neuritis–Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:540156. DOI:10.3389/fneur.2020.540156</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. DOI:10.1186/s12974-016-0718-0</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572. DOI:10.1212/NXI.0000000000000572</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Peschl P, Bradl M, Höftberger R, et al. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front Immunol. 2017;8:529. DOI:10.3389/fimmu.2017.00529</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018;195:8-15. DOI:10.1016/j.ajo.2018.07.020</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1100. DOI:10.1212/NXI.0000000000001100</mixed-citation></ref></ref-list></back></article>
